中国人群早孕期联合筛查中生物标志物测量质量标准评估:一项多中心研究
该前瞻性多中心横断面研究纳入中国六家三级医院的22066例单胎妊娠,评估基于欧洲人群开发的MoM模型在中国早孕期子痫前期联合筛查中的适用性。结果显示,排除各中心初始400例后,所有PlGF的MoM分布需要重新中心化,而MAP并非全部需要;重新中心化后MAP和PlGF的MoM中位数分别为1.003和1.004。作者认为中国中心应评估初始病例的生物标志物MoM分布,以确保符合风险估计模型假设的集中趋势。
要点
- 中国六家三级医院22066例早孕期单胎妊娠纳入分析。
- 排除各中心初始400例后,所有PlGF的MoM分布需重新中心化,MAP并非全部需要。
- 重新中心化后MAP和PlGF的MoM中位数分别为1.003和1.004。
核心结论
- 中国开展子痫前期联合筛查的中心应评估初始病例的生物标志物MoM分布,以确保其符合风险估计模型假设的集中趋势。
研究设计与样本
- 前瞻性多中心横断面研究,纳入中国六家三级医院孕11+0至13+6周接受早产型子痫前期筛查的22066例单胎妊娠。
- 测量平均动脉压(MAP)和胎盘生长因子(PlGF),使用商业软件中胎儿医学基金会MoM模型转换为MoM值,PlGF另用中国开发的免疫分析法测定。
主要发现
- 排除各中心初始400例妊娠后,所有PlGF的MoM分布需要重新中心化,而MAP的MoM分布并非全部需要重新中心化。
- 重新中心化后,MAP和PlGF的总体分布MoM中位数(95%置信区间)分别为1.003(1.001, 1.004)和1.004(0.996, 1.013)。
关键数值与推荐
- 分布集中趋势良好定义为MoM中位数在0.95至1.05之间,可接受定义为在1.05至1.10之间。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In 22 066 first-trimester pregnancies from six Chinese hospitals, biomarker measurements required recalibration to align with the established risk model. Continuous quality assurance is essential to ensure accurate preeclampsia risk assessment when implementing combined screening in new populations. Abstract Introduction The first-trimester combined screening test for preterm preeclampsia (preterm-PE) has been implemented in Mainland China. This study aims, first, to evaluate the applicability of multiple of the median (MoM) models based on biomarkers developed and utilized in a European population for prospective preterm-PE screening in Mainland China; second, to assess the criteria for biomarker adjustment; and third, to establish criteria for continuous quality assurance in the screening process. Material and Methods In this prospective multicenter cross-sectional study, 22 066 singleton pregnancies undergoing preterm-PE screening at 11 + 0–13 + 6 weeks were recruited from six tertiary hospitals in Mainland China. Mean arterial pressure (MAP) and placental growth factor (PlGF) were measured and converted to their equivalent MoM values using Fetal Medicine Foundation MoMing models incorporated in commercial software. PlGF levels were also determined using immunoassays developed in China. MoM and log10MoM distributions in the initial screened subjects were assessed for (1) central tendency and dispersion and (2) whether biomarker MoM distributions needed to be recentered. Biomarker central tendency and temporal stability both before and after recentering were assessed using Cumulative Sum plots. Distribution central tendency was considered good if its median MoM was between 0.95 and 1.05 and acceptable if between 1.05 and 1.10. Results After excluding the initial 400 pregnancies from each center, all PlGF, but not all MAP MoM distributions, required recentering. Post-recentering, the overall distribution median (95% confidence interval) MoM values for MAP and PlGF were 1.003 (1.001, 1.004) and 1.004 (0.996, 1.013), respectively. Conclusions Chinese centers performing combined PE screening should assess biomarker MoM distributions in their initial cases to ensure that they conform to the expected central tendencies assumed in the risk estimation models.
引用
- Acta Obstetricia et Gynecologica Scandinavica:Assessing quality standards of biomarker measurement in first‐trimester combined screening for preeclampsia in the Chinese population: A multicenter study
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。